Author:
Azzopardi Ernest A.,Refalo Azzopardi Sarah,Tretti Clementoni Matteo,Boyce Dean Edward,Sadideen Hazim,Mosahebi Ash
Abstract
Xanthelasma palpebrarum is the most common type of cutaneous xanthoma and is often a cause of psychological distress and aesthetic dissatisfaction. The extent, depth, or background skin type, intolerance to downtime, or cost, may restrict the treatment options, or contribute to a recurrence rate of up to 60%. 1470 nm microfiber laser is a recent clinical innovation that allows highly targeted delivery of Laser to deeper tissues through fibers as small as 150 μm in diameter, targeting fat and/or water chromophores. We report a retrospective data series on five patients (10 eyelids) treated with intralesional microfiber laser, where other treatment methods were inappropriate, contraindicated, or declined. Single-use tip firing microfibers (150-300 μm), were introduced into lesions under tactile and visible indicator light guidance (1-2 W; 250-500 Hz, LEED 1-2 Jcm–2, 1470 nm ). Results were followed up with before/after photography. The pain was measured using a prevalidated 1-10 Likert scale. Patients were followed up by remote consultation up to one year post-treatment. Xanthelasma size was (7 mm ± 4 mm, mean ±SD). The average time to complete resolution was 12±2.4 weeks ( All patients were normolipidemic pre-treatment. Sessions needed were 1.2±0.4 (mean ±SD). Maximum discomfort on a 1-10 Likert scale was 3±1/10 (mean ±SD), at eight weeks’ follow-up. No recurrences were reported up to 1 year’s follow-up. No patients had visible scarring. Most importantly, all patients reported minimal downtime and could continue normally with activities of daily life. 1470 nm microfiber laser is a promising method for the management of palpebral xanthelasma: within this case series was safe and effective in experienced hands. Further, larger studies are in hand to assess follow-up long-term outcomes and patient satisfaction.
Subject
Biomedical Engineering,Surgery
Reference20 articles.
1. Howick J, Phillips B, Ball C, Sackett D, Badenoch D. Oxford centre for evidence-based medicine levels of evidence. University of Oxford, Centre for Evidence-Based Medicine 2009.
2. Rohrich RJ, Janis JE, Pownell PH. Xanthelasma palpebrarum: a review and current management principles. Plastic Reconstruct Surg 2002:110:1310-14.
3. Lee HY, Jin US, Minn KW, Park Y-O. Outcomes of surgical management of xanthelasma palpebrarum. Arch Plastic Surg 2013:40:380.
4. Hawash AA, Ingrasci G, Nouri K, Yosipovitch G. Pruritus in keloid scars: mechanisms and treatments. Acta Dermato-Venereologica 2021:101:adv00582-adv82.
5. Esmat SM, Elramly AZ, Abdel Halim DM, et al. Fractional CO2 laser is an effective therapeutic modality for xanthelasma palpebrarum: a randomized clinical trial. Dermatol Surg 2014;40:1349-55.